Emerging therapies in adult and paediatric bronchiectasis

Respirology

Volumn 23, Issue 12, 2018, Pages 1127-1137

  Regan, Kate H ^a,b   Hill, Adam T ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

anti inflammatory; bronchiectasis; phage therapy; pulmonary infection

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALVELESTAT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ATORVASTATIN; BAY 85 8501; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; DIPEPTIDYL PEPTIDASE 1 INHIBITOR; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSTIMULATING AGENT; INS 1007; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; N [2 (2,3 DIFLUOROBENZYLTHIO) 6 (2,3 DIHYDROXY 1 METHYLPROPOXY) 4 PYRIMIDINYL] 1 AZETIDINESULFONAMIDE; OM 85; PEPTIDE HYDROLASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; UNCLASSIFIED DRUG; VITAMIN D; VX 371;

ADJUVANT THERAPY; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIOPHAGE; BRONCHIECTASIS; BRONCHITIS; DISEASE EXACERBATION; HUMAN; INFLAMMATORY INFILTRATE; LUNG INFECTION; LUNG INJURY; MUCOCILIARY CLEARANCE; NEUTROPHIL; NONHUMAN; PHAGE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; REVIEW; VITAMIN D DEFICIENCY; ADULT; CHILD; DRUG EFFECT; IMMUNOLOGY; PATIENT CARE; PROCEDURES;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHIECTASIS; CHILD; HUMANS; MUCOCILIARY CLEARANCE; PATIENT CARE MANAGEMENT;

EID: 85053760374     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.13407     Document Type: Review

References (106)

1. Wurzel DF, Chang AB. An update on pediatric bronchiectasis. Expert Rev. Respir. Med. 2017; 11: 517–32
2. Chalmers JD. Bronchiectasis: phenotyping a complex disease. COPD 2017; 14: S12–8
3. Laennec RTH, Forbes SJ. A Treatise on the Diseases of the Chest, and on Mediate Auscultation. Samuel S. and William Wood, London, 1819
4. Quint JK, Millett ERC, Joshi M, Navaratnam V, Thomas SL, Hurst JR, Smeeth L, Brown JS. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur. Respir. J. 2016; 47: 186–93
5. Hill AT, Routh C, Welham S. National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care? Thorax 2014; 69: 292–4
6. Kapur N, Masel JP, Watson D, Masters IB, Chang AB. Bronchoarterial ratio on high-resolution CT scan of the chest in children without pulmonary pathology: need to redefine bronchial dilatation. Chest 2011; 139: 1445–50
7. Chang AB, Byrnes CA, Everard ML. Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis. Paediatr. Respir. Rev. 2011; 12: 97–103
8. Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR. Emerging drugs for bronchiectasis: an update. Expert Opin. Emerg. Drugs 2015; 20: 277–97
9. Gao Y-H, Guan W-J, Liu S-X, Wang L, Cui J-J, Chen R-C, Zhang G-J. Aetiology of bronchiectasis in adults: a systematic literature review. Respirology 2016; 21: 1376–83
10. Kumar A, Lodha R, Kumar P, Kabra SK. Non-cystic fibrosis bronchiectasis in children: clinical profile, etiology and outcome. Indian Pediatr. 2015; 52: 35–7
11. Gupta S, Siddiqui S, Haldar P, Raj JV, Entwisle JJ, Wardlaw AJ, Bradding P, Pavord ID, Green RH, Brightling CE. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136: 1521–8
12. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55: 635–42
13. Martínez-García MÁ, Soler-Cataluña JJ, Donat Sanz Y, Catalán Serra P, Agramunt Lerma M, Ballestín Vicente J, Perpiñá-Tordera M. Factors associated with bronchiectasis in patients with COPD. Chest 2011; 140: 1130–7
14. Mao B, Lu H-W, Li M-H, Fan L-C, Yang J-W, Miao X-Y, Xu J-F. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Sci. Rep. 2015; 5: 10961
15. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005; 128: 739–45
16. Olveira C, Olveira G, Gaspar I, Dorado A, Cruz I, Soriguer F, Quittner AL, Espildora F. Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life. Qual. Life Res. 2013; 22: 597–605
17. Hester KLM, Macfarlane JG, Tedd H, Jary H, McAlinden P, Rostron L, Small T, Newton JL, De Soyza A. Fatigue in bronchiectasis. QJM 2012; 105: 235–40
18. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. 1997; 10: 1754–60
19. Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur. Respir. J. 2018; 51: 1701953
20. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am. J. Med. 2000; 109: 288–95
21. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2012; 186: 657–65
22. Chalmers JD, Elborn JS. Reclaiming the name ‘bronchiectasis. Thorax 2015; 70: 399–400
23. Redondo M, Keyt H, Dhar R, Chalmers JD. Global impact of bronchiectasis and cystic fibrosis. Breathe 2016; 12: 222–35
24. Chang AB. Bronchiectasis: so much yet to learn and to do. Paediatr. Respir. Rev. 2011; 12: 89–90
25. Cole PJ. Inflammation: a two-edged sword – the model of bronchiectasis. Eur. J. Respir. Dis. Suppl. 1986; 147: 6–15
26. Gaillard EA, Carty H, Heaf D, Smyth RL. Reversible bronchial dilatation in children: comparison of serial high-resolution computer tomography scans of the lungs. Eur. J. Radiol. 2003; 47: 215–20
27. Hill AT, Bilton D, Brown J, Burns G, Calvert J, Heslop K, Lim WS, Manzie J, Pasteur M, Sinfield F et al. British Thoracic Society quality standards for clinically significant bronchiectasis in adults. Br. Thorac. Soc. Rep. 2012; 4: 1–16
28. Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst. Rev. 2014: CD010327
29. Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst. Rev. 2009: CD000996
30. Lasserson TJ, Holt K, Evans DJ, Milan SJ, Greenstone M. Anticholinergic therapy for bronchiectasis. Cochrane Database Syst. Rev. 2001: CD002163
31. Murray MP, Govan JRW, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2011; 183: 491–9
32. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 481–5
33. Aksamit T, De Soyza A, Bandel T-J, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2018; 51: 1702053
34. De Soyza A, Aksamit T, Bandel T-J, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2018; 51: 1702052
35. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 1994; 331: 637–42
36. Wilkinson M, Sugumar K, Milan SJ, Hart A, Crockett A, Crossingham I. Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. 2014: CD001289
37. Barker AF, O'Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir. Med. 2014; 2: 738–49
38. McCubbrey AL, Curtis JL. Efferocytosis and lung disease. Chest 2013; 143: 1750–7
39. Pragman AA, Berger JP, Williams BJ. Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms. Clin. Pulm. Med. 2016; 23: 57–66
40. Döring G. The role of neutrophil elastase in chronic inflammation. Am. J. Respir. Crit. Care Med. 1994; 150: S114–7
41. Sinha S, Watorek W, Karr S, Giles J, Bode W, Travis J. Primary structure of human neutrophil elastase. Proc. Natl. Acad. Sci. U. S. A. 1987; 84: 2228–32
42. Voynow JA, Fischer BM, Zheng S. Proteases and cystic fibrosis. Int. J. Biochem. Cell Biol. 2008; 40: 1238–45
43. Pandey KC, De S, Mishra PK. Role of proteases in chronic obstructive pulmonary disease. Front. Pharmacol. 2017; 8: 512
44. Schaaf B, Wieghorst A, Aries SP, Dalhoff K, Braun J. Neutrophil inflammation and activation in bronchiectasis: comparison with pneumonia and idiopathic pulmonary fibrosis. Respiration 2000; 67: 52–9
45. Stevens T, Ekholm K, Gränse M, Lindahl M, Kozma V, Jungar C, Ottosson T, Falk-Håkansson H, Churg A, Wright JL et al. AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J. Pharmacol. Exp. Ther. 2011; 339: 313–20
46. Gunawardena KA, Gullstrand H, Perrett J. Pharmacokinetics and safety of AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients with COPD. Int. J. Clin. Pharmacol. Ther. 2013; 51: 288–304
47. Stockley R, De Soyza A, Gunawardena K, Perrett J, Forsman-Semb K, Entwistle N, Snell N. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir. Med. 2013; 107: 524–33
48. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am. J. Respir. Crit. Care Med. 1997; 156: 536–41
49. Elborn JS, Perrett J, Forsman-Semb K, Marks-Konczalik J, Gunawardena K, Entwistle N. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur. Respir. J. 2012; 40: 969–76
50. Kuna P, Jenkins M, O'Brien CD, Fahy WA. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respir. Med. 2012; 106: 531–9
51. Mereo BioPharma. AZD-9668 (Alvelestat). Mereo BioPharma Pipeline. Available from URL: http://www.mereobiopharma.com/pipeline/azd-9668-alvelestat/. Accessed 30 March 18
52. Watz H, Pedersen F, Kirsten A, Nagelschmitz J, Bandel T-J, Schwers S, Rabe K. Safety and tolerability of the NE inhibitor BAY 85-8501 in patients with non-CF bronchiectasis. Eur. Respir. J. 2016; 48: PA4088
53. Nagelschmitz J, Becka M, Kaufel D, Schwers S, Wensing G. The novel elastase inhibitor BAY 85-8501: bioavailability and food effect study to evaluate pharmacokinetics of tablet formulations. Eur. Respir. J. 2014; 44: P1511
54. Hazari YM, Bashir A, Habib M, Bashir S, Habib H, Qasim MA, Shah NN, Haq E, Teckman J, Fazili KM. Alpha-1-antitrypsin deficiency: genetic variations, clinical manifestations and therapeutic interventions. Mutat. Res. 2017; 773: 14–25
55. Araújo D, Sucena M. Association between alpha 1 antitrypsin and bronchiectasis. Eur. Respir. J. 2015; 46: PA1248
56. Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 2007; 176: 1215–21
57. Cantin AM, Berthiaume Y, Cloutier D, Martel M. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin. Invest. Med. 2006; 29: 201–7
58. Turk D, Janjić V, Štern I, Podobnik M, Lamba D, Weis Dahl S, Lauritzen C, Pedersen J, Turk V, Turk B. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J. 2001; 20: 6570–82
59. Palmér R, Mäenpää J, Jauhiainen A, Larsson B, Mo J, Russell M, Root J, Prothon S, Chialda L, Forte P et al. Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects. Clin. Pharmacol. Ther. 2018. https://doi.org/10.1002/cpt.1053
60. Stenvall K, Mo J, Russel M, Gardiner P, Palmer R, Jauhiainen A, Maenpaa J, Root J, Larsson B. Target engagement confirmed in man with a dipeptidyl peptidase 1 inhibitor. Eur. Respir. J. 2017; 50: PA3251
61. About INS1007. Insmed. Available from URL: http://www.insmed.com/about-ins1007/. Accessed 30 March 18
62. Gerard C, Rollins BJ. Chemokines and disease. Nat. Immunol. 2001; 2: 108–15
63. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol. Ther. 2009; 121: 55–68
64. Gaga M, Bentley AM, Humbert M, Barkans J, O'Brien F, Wathen CG, Kay AB, Durham SR. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53: 685–91
65. Chen AC-H, Martin ML, Lourie R, Rogers GB, Burr LD, Hasnain SZ, Bowler SD, McGuckin MA, Serisier DJ. Adult non-cystic fibrosis bronchiectasis is characterised by airway luminal Th17 pathway activation. PLoS One 2015; 10: e0119325
66. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126: 926–34
67. De Soyza A, Pavord I, Elborn JS, Smith D, Wray H, Puu M, Larsson B, Stockley R. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur. Respir. J. 2015; 46: 1021–32
68. O'Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, Larsson B, Cullberg M, Nair P. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 2016; 4: 797–806
69. Kirsten AM, Förster K, Radeczky E, Linnhoff A, Balint B, Watz H, Wray H, Salkeld L, Cullberg M, Larsson B. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm. Pharmacol. Ther. 2015; 31: 36–41
70. Kawamatawong T. Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J. Thorac. Dis. 2017; 9: 1144–54
71. Sousa LP, Lopes F, Silva DM, Tavares LP, Vieira AT, Rezende BM, Carmo AF, Russo RC, Garcia CC, Bonjardim CA et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner. J. Leukoc. Biol. 2010; 87: 895–904
72. Roflumilast for treating chronic obstructive pulmonary disease|Guidance and guidelines|NICE. Available from URL: https://www.nice.org.uk/guidance/ta461/chapter/1-Recommendations. Accessed 30 March 18
73. Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 81–90
74. Park J. Effect of roflumilast(Daxas®) in patients with symptomatic non-cystic fibrosis bronchiectasis. Non-Cystic Fibrosis Bronchiectasis Thematic Poster Session. Am. J. Respir. Crit. Care Med. 2014; 189: A6255
75. De Benedetto F, Sevieri G. Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art. Multidiscip. Respir. Med. 2013; 8: 33
76. Gutiérrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest 2001; 119: 1742–8
77. Jara-Pérez JV, Berber A. Primary prevention of acute respiratory tract infections in children using a bacterial immunostimulant: a double-masked, placebo-controlled clinical trial. Clin. Ther. 2000; 22: 748–59
78. Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J. Pediatr. 2010; 6: 5–12
79. Solèr M, Mütterlein R, Cozma G. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007; 74: 26–32
80. Collet JP, Shapiro S, Ernst P, Renzi P, Ducruet T, Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1997; 156: 1719–24
81. Koatz AM, Coe NA, Cicerán A, Alter AJ. Clinical and immunological benefits of OM-85 bacterial lysate in patients with allergic rhinitis, asthma, and COPD and recurrent respiratory infections. Lung 2016; 194: 687–97
82. Gao J, Gao X, Kong L. To investigate the prevention of OM-85 on bronchiectasis exacerbations (iPROBE) in Chinese patients: study protocol for a randomized controlled trial. Trials 2014; 15: 150
83. Bivona G, Agnello L, Ciaccio M. Vitamin D and immunomodulation: is it time to change the reference values? Ann. Clin. Lab. Sci. 2017; 47: 508–10
84. Chalmers JD, McHugh BJ, Docherty C, Govan JRW, Hill AT. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013; 68: 39–47
85. Ginde AA, Mansbach JM, Camargo CA. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2009; 169: 384–90
86. Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, Islam K, McLaughlin D, Bhowmik A, Timms PM et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Lancet Respir. Med. 2015; 3: 120–30
87. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Dowling RB, Cole PJ, Wilson R. Systemic markers of inflammation in stable bronchiectasis. Eur. Respir. J. 1998; 12: 820–4
88. Navaratnam V, Millett ERC, Hurst JR, Thomas SL, Smeeth L, Hubbard RB, Brown J, Quint JK. Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax 2017; 72: 161–6
89. Blanco-Colio LM, Tuñón J, Martín-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003; 63: 12–23
90. Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J. Am. Soc. Nephrol. 2002; 13: 1673–81
91. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am. J. Med. 2008; 121: 1002–7.e1
92. Boyd AR, Hinojosa CA, Rodriguez PJ, Orihuela CJ. Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia. BMC Microbiol. 2012; 12: 73
93. Mandal P, Chalmers JD, Graham C, Harley C, Sidhu MK, Doherty C, Govan JW, Sethi T, Davidson DJ, Rossi AG et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir. Med. 2014; 2: 455–63
94. Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur. Respir. J. 2009; 34: 125–31
95. Bedi P, Chalmers JD, Graham C, Clarke A, Donaldson S, Doherty C, Govan JRW, Davidson DJ, Rossi AG, Hill AT. A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with Pseudomonas aeruginosa: a proof of concept study. Chest 2017; 152: 368–78
96. Lucas JS, Burgess A, Mitchison HM, Moya E, Williamson M, Hogg C; On Behalf of the National PCD Service UK. Diagnosis and management of primary ciliary dyskinesia. Arch. Dis. Child. 2014; 99: 850–6
97. Hanukoglu I, Hanukoglu A. Epithelial sodium channel (ENaC) family: phylogeny, structure-function, tissue distribution, and associated inherited diseases. Gene 2016; 579: 95–132
98. Bangel N, Dahlhoff C, Sobczak K, Weber W-M, Kusche-Vihrog K. Upregulated expression of ENaC in human CF nasal epithelium. J. Cyst. Fibros. 2008; 7: 197–205
99. Parion Sciences. ENaC Pulmonary (VX-371/P-1037). ENaC Pulm VX-371P-1037. 2017. Available from URL: http://www.parion.com/pipeline/enac-pulmonary-vx371-p1037/. Accessed 30 March 18
100. Angrill J, Agustí C, de Celis R, Rañó A, Gonzalez J, Solé T, Xaubet A, Rodriguez-Roisin R, Torres A. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15–9
101. Alanin MC, Nielsen KG, von Buchwald C, Skov M, Aanaes K, Høiby N, Johansen HK. A longitudinal study of lung bacterial pathogens in patients with primary ciliary dyskinesia. Clin. Microbiol. Infect. 2015; 21: 1093.e1–7
102. Renée Crowther Labiris N, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. Am. J. Respir. Crit. Care Med. 1999; 160: 1711–6
103. Yapa S, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJH et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob. Agents Chemother. 2014; 58: 2570–9
104. Twort FW. The discovery of the “bacteriophage”. Lancet 1925; 205: 845
105. Abedon ST. Phage therapy of pulmonary infections. Bacteriophage 2015; 5: e1020260
106. Waters EM, Neill DR, Kaman B, Sahota JS, Clokie MRJ, Winstanley C, Kadioglu A. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 2017; 72: 666–7